Additional devices to be used with pen injectors

Diglas et al, 199922657 adult patients with type 1 diabetes
Aged 19–60 years
NovoPen 3
NovoPen 3 with PenMate®
Trial length: two 6-week periods
  1. Glycaemic control (mean HbA1c)
  2. Pain perception (measured on a 100 mm visual analogue scale of pain perception)
  1. 8.2 vs. 8.1% ( p = 0.2)
  2. Pain perception: 14.9 vs. 19.9 mm (p = 0.005)
    Experienced pain 3–6 times a week: 10.5% vs. 22.8%
  3. 62 vs. 66 (p = 0.3)
No description of how randomisation took placeComparative multicentre crossoverIb

From: Evidence tables

Cover of Type 1 Diabetes
Type 1 Diabetes: Diagnosis and Management of Type 1 Diabetes in Children and Young People.
NICE Clinical Guidelines, No. 15.2.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2004 Sep.
Copyright © 2004, National Collaborating Centre for Women’s and Children’s Health.

Apart from any fair dealing for the purposes of research or private study, criticism or review, as permitted under the Copyright, Designs and Patents Act, 1988, no part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

The rights of National Collaborating Centre for Women’s and Children’s Health to be identified as Author of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.